Stockreport

Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]

Vor Biopharma Inc.  (VOR) 
PDF Vor Biopharma (VOR) has jumped onto investors' radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that fram [Read more]